Covaccine is the first indigenous vaccine made in India against the corona virus, which the company has developed in collaboration with ICMR.
Bharat Biotech’s Vaccine Covaccine (Symbol photo)
The data of Phase-3 clinical trial of Bharat Biotech’s COVID-19 vaccine ‘Covaccine’ has been revealed. The news agency ANI has quoted sources as saying that in the third phase clinical trial, the vaccine has been 77.8 percent effective. However, detailed information about the data has not been revealed yet.
Bharat Biotech recently submitted data of Phase-3 clinical trials to the Government of India. After which the Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is reviewing it. After review, the SEC will send the data to DCGI.
Covaccine is the first indigenous vaccine made in India against the corona virus, which the company has developed in collaboration with the Indian Council of Medical Research (ICMR). Questions have been raised many times about the Phase-3 trial data of Covaccine, because its use was approved without final results. However, Bharat Biotech said a few days ago that the company has published 9 research papers regarding the safety and effectiveness of the vaccine.
WHO meeting regarding covaccine
The World Health Organization (WHO) has also accepted Bharat Biotech’s Expression of Interest (EoI) for the vaccine. In the WHO meeting on Wednesday, the data of the Phase III trial of the vaccine will be reviewed. In this meeting, a decision can be taken to include Kovaxin in the list of WHO for emergency use. If the WHO includes Covaccine in its list, then such people will be able to go abroad, who have taken the dose of Covaccine.
Earlier on June 12, the company said that the first and second phase trials of Covaxin vaccine were published in the famous journal ‘The Lancet’. Bharat Biotech said, “At present, data from the Phase III trial on the efficacy and safety of Covaxin is being analyzed and compiled. Along with this, it has been ensured that its purity is not compromised. The company will soon make public the data of Phase III trials.
Also read- Everyday goods became costlier by 40%, inflation of flour and oil spoiled the budget, broke record of 15 months
Also read- Big news: Now Jet Airways will fly again, revival plan has been approved, now the slot will be decided
.
